Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows: - generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment; - other (6%) : primarily active pharmaceutical ingredients. At the end of March 2021, the group had 44 production plants worldwide. Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).

Employees

43,000

Sector

Pharmaceuticals

Calendar

2025-02-03 - Q3 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-09	1,806.65 ₹	+0.10%	1,528,215
24-12-06	1,804.85 ₹	-0.47%	1,590,478
24-12-05	1,813.45 ₹	+0.74%	2,742,263
24-12-04	1,800.20 ₹	+0.01%	2,320,116
24-12-03	1,800.05 ₹	-0.47%	1,543,970

Delayed Quote NSE India S.E., December 09, 2024 at 03:16 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart SUN-PHARMACEUTICAL-INDUST

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,804.85INR

Average target price

2,047.11INR

Spread / Average Target

+13.42%

Consensus

Profit revisions

estimates-change-chart SUN-PHARMACEUTICAL-INDUST

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart SUN-PHARMACEUTICAL-INDUST

Company calendar

Market Closed - NSE India S.E. Other stock markets 06:49:38 2024-12-09 am EST			5-day change	1st Jan Change
1,806.65 ^INR	+0.10%		+1.45%	+43.45%

Dec. 03	Exclusive-Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms	RE
Nov. 29	Indian Equities Rebound on Friday, Aided by Heavyweights, Pharma Names	MT

Capitalization	4,330B 51.13B 48.39B 44.86B 40.12B 72.29B 80.03B 558B 206B 1,779B 192B 188B 7,666B	P/E ratio 2025 *	37.7x	P/E ratio 2026 *	32.7x
Enterprise value	4,090B 48.29B 45.7B 42.37B 37.89B 68.28B 75.59B 527B 195B 1,680B 181B 177B 7,240B	EV / Sales 2025 *	7.73x	EV / Sales 2026 *	6.81x
Free-Float	-	Yield 2025 *	0.78%	Yield 2026 *	0.86%

Exclusive-Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms	Dec. 03	RE
Indian Equities Rebound on Friday, Aided by Heavyweights, Pharma Names	Nov. 29	MT
Sun Pharmaceutical Industries Limited Receives Order from Regional Director, North Western Region, Ministry of Corporate Affairs	Nov. 28	CI
Sun Pharmaceutical Industries Limited and Sun Pharma Laboratories Limited Receive Order from Office of the Commissioner of Customs,, Mumbai	Nov. 26	CI
Indian Equities Tank on Tuesday as Investors Keep 'Sell on Rise' Strategy	Nov. 12	MT
Sun Pharmaceutical Industries Limited Receives Order from Regional Director, North Western Region, Ministry of Corporate Affairs	Nov. 06	CI
Sun Pharmaceutical Industries Limited Receives Order from Office of the Commissioner of Customs, NS-I, Adjudication Cell, Maharashtra	Nov. 05	CI
Nomura Adjusts Sun Pharmaceutical Industries' Price Target to INR1,850 From INR1,444, Keeps at Neutral	Oct. 30	MT
Jefferies Adjusts Sun Pharmaceutical Industries' Price Target to INR2,150 From INR2,000, Keeps at Buy	Oct. 29	MT
Global markets live: Eurofins, Blackstone, Google Boeing, Apple...	Oct. 28
Sun Pharmaceutical Industries Limited, Q2 2025 Earnings Call, Oct 28, 2024	Oct. 28
India's Sun Pharma beats Q2 profit estimates on strong sales	Oct. 28	RE
Sun Pharmaceutical Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Oct. 28	CI

Nomura Adjusts Sun Pharmaceutical Industries' Price Target to INR1,850 From INR1,444, Keeps at Neutral	Oct. 30	MT
Jefferies Adjusts Sun Pharmaceutical Industries' Price Target to INR2,150 From INR2,000, Keeps at Buy	Oct. 29	MT
Jefferies Adjusts Sun Pharmaceutical Industries' Price Target to INR2,000 From INR1,785, Keeps at Buy	Aug. 02	MT
Jefferies Adjusts Sun Pharmaceutical Industries’ Price Target to INR1,585 From INR1,535, Keeps at Buy	Feb. 01	MT
Nomura Adjusts Sun Pharmaceutical Industries' Price Target to INR1,279 From INR1,313, Keeps at Buy	Nov. 03	MT

Sun Pharmaceutical Industries Ltd. Stock

Equities

SUNPHARMA

INE044A01036

Pharmaceuticals

Valuation: Sun Pharmaceutical Industries Ltd.

Chart: Sun Pharmaceutical Industries Ltd.

Latest news: Sun Pharmaceutical Industries Ltd.

Last Transcript: Sun Pharmaceutical Industries Ltd.

Analysts' recommendations: Sun Pharmaceutical Industries Ltd.

Press Releases: Sun Pharmaceutical Industries Ltd.

News in other languages: Sun Pharmaceutical Industries Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Sun Pharmaceutical Industries Ltd.

ETFs: Sun Pharmaceutical Industries Ltd.

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Healthcare \| July And August 2024 - Case Laws	Nov. 25	AQ
Analysis Group - Reports by Managing Principal John Jarosz Cited in Grant of Preliminary Injunction in Patent Infringement Case	Nov. 13	AQ
Sun Pharma Presents LEQSELVI Data Highlighting Clinical Efficacy and Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference	Oct. 28	AQ
Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for commercializing the specialty product FIBROMUN	Oct. 02	AQ
Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain	Sep. 09	AQ

En Direct des Marchés : GTT relève ses objectifs, Eurofins investit, cure d'austérité chez Volkswagen	Oct. 28
Les marchés ne savent plus où donner de la tête	Oct. 28
La renta variable de India sube un 0,2% liderada por los bancos -- Market Talk	Oct. 10
La renta variable de India cae un 0,3% por los posibles ajustes de posiciones -- Market Talk	Sep. 27
En Direct des Marchés : Société Générale, Veolia, Atos, Worldline, BAE Systems, Meta, ARM, Volkswagen...	Aug. 01

1 day	-0.25%
1 week	-0.45%
Current month	+1.09%
1 month	+0.32%
3 months	-1.18%
6 months	+18.99%
Current year	+42.95%

Director	Title	Age	Since
Aalok Shanghvi CEO	Chief Executive Officer	-	-
Dilip Shantilal Shanghvi CEO	Chief Executive Officer	68	1982-12-31
C. S. Muralidharan DFI	Director of Finance/CFO	-	2017-06-18

Manager	Title	Age	Since
Dilip Shantilal Shanghvi CHM	Chairman	68	-
Sudhir Vrundavandas Valia BRD	Director/Board Member	67	1993-12-31
Gautam Bhailal Doshi BRD	Director/Board Member	72	2018-05-24

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.23%	-0.45%	+45.03%	+136.97%	51.13B
OTSUKA HOLDINGS CO., LTD.	-0.27%	-0.73%	+54.24%	+112.23%	31.65B
SANDOZ GROUP AG	-0.17%	-1.77%	+40.74%	-	19.18B
CIPLA LIMITED	-0.29%	-2.34%	+22.47%	+64.61%	14.09B
ZYDUS LIFESCIENCES LIMITED	-0.82%	+1.25%	+55.73%	+113.39%	11.82B
THE MEDICINES COMPANY	-.--%	+0.14%	-	-	6.79B
STADA ARZNEIMITTEL	-.--%	-1.95%	-	-	5.73B
ONO PHARMACEUTICAL CO., LTD.	-1.47%	-1.27%	-34.34%	-38.26%	5.44B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.54%	-4.31%	+2.08%	+19.01%	5.11B
GLENMARK PHARMACEUTICALS LIMITED	-0.97%	-2.20%	+84.77%	+198.07%	5.09B
Average	-0.48%	-0.77%	+33.84%	+86.57%	15.6B
Weighted average by Cap.	-0.35%	-0.10%	+42.03%	+110.22%

	2025 *	2026 *
Net sales	529B 6.25B 5.91B 5.48B 4.9B 8.83B 9.78B 68.18B 25.21B 217B 23.47B 22.94B 937B	587B 6.93B 6.56B 6.08B 5.43B 9.79B 10.84B 75.62B 27.96B 241B 26.02B 25.45B 1,039B
Net income	115B 1.36B 1.29B 1.19B 1.07B 1.92B 2.13B 14.83B 5.48B 47.29B 5.11B 4.99B 204B	133B 1.57B 1.48B 1.38B 1.23B 2.22B 2.45B 17.12B 6.33B 54.57B 5.89B 5.76B 235B
Net Debt	-240B -2.84B -2.69B -2.49B -2.23B -4.01B -4.44B -30.99B -11.46B -98.81B -10.67B -10.43B -426B	-332B -3.93B -3.71B -3.44B -3.08B -5.55B -6.14B -42.84B -15.84B -137B -14.75B -14.42B -588B